TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Hangzhou Tigermed Consulting Co., Ltd. Class H ( (HK:3347) ).
Hangzhou Tigermed Consulting Co., Ltd. has established a Nomination Committee to enhance its corporate governance structure by improving the appointment procedures for directors and senior management. This committee is tasked with nominating candidates for these positions, ensuring a balanced and diverse board composition, and making recommendations on selection criteria and procedures. The initiative is expected to strengthen the company’s governance framework, potentially impacting its operational efficiency and stakeholder confidence.
The most recent analyst rating on (HK:3347) stock is a Sell with a HK$37.00 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.
More about Hangzhou Tigermed Consulting Co., Ltd. Class H
Hangzhou Tigermed Consulting Co., Ltd. operates in the consulting industry, focusing on providing clinical trial services and contract research organization (CRO) services. The company is known for its expertise in clinical development and regulatory affairs, serving pharmaceutical and biotechnology companies globally.
Average Trading Volume: 4,878,203
Technical Sentiment Signal: Buy
Current Market Cap: HK$55.09B
Learn more about 3347 stock on TipRanks’ Stock Analysis page.